Pricing
Prices are indicative MRP and may vary by pharmacy. Trend compares against the last recorded price.
All price changes →Indications & Uses
Rasagil is indicated for:
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
The recommended dose is 1 mg orally once daily as monotherapy or as adjunct therapy in patients not taking levodopa. In patients taking levodopa, with or without other PD drugs (e.g., dopamine agonist, amantadine, anticholinergics), the recommended initial dose of Rasagiline is 0.5 mg once daily. If the patient tolerates the daily 0.5 mg dose, but a sufficient clinical response is not achieved, the dose may be increased to 1 mg once daily. When Rasagiline is used in combination with levodopa, a reduction of the levodopa dose may be considered, based upon individual response. The recommended dose of Rasagiline should not be exceeded because of risk of hypertension.Pediatric use: The safety & effectiveness in pediatric patients have not been established.Geriatric use: There were no significant differences in the safety profile of the geriatric & nongeriatric patients.
Side Effects
Side effects include joint pain, mild headache, depressed mood, dizziness, spinning sensation, hair loss, mild skin rash, numbness or tingly feeling, dry mouth, loss of appetite, constipation, diarrhea, stomach pain or upset, vomiting, weight loss etc.
Cautions & Contraindications
Warnings & Precautions
Hypertension: Exacerbation of hypertension may occur during treatment with Rasagil. Medication adjustment may be necessary if elevation of blood pressure is sustained. Dietary tyramine restriction is not required during treatment with recommended doses of Rasagil. However, certain foods that may contain very high amounts (more than 150 mg) of tyramine that could potentially cause severe hypertension because of tyramine interaction in patients taking Rasagil, even at the recommended doses, due to increased sensitivity to tyramine. In that case, patients should be advised to avoid foods containing a very large amount of tyramine.Serotonin Syndrome: Serotonin syndrome has been reported with concomitant use of an antidepressant (e.g., SSRIs, SNRIs, tricyclic & tetracyclic antidepressants, Triazolopyridine antidepressants) and a nonselective MAOI (e.g., phenelzine, tranylcypromine) or selective MAO-B inhibitors, such as Rasagil.Ciprofloxacin or other CYP1A2 Inhibitors: Patients taking concomitant ciprofloxacin or other CYP1A2 inhibitors should not exceed a dose of Rasagil 0.5 mg once daily.Hepatic impairment: Patients with mild hepatic impairment should be given the dose of Rasagil 0.5 mg once daily. Rasagil should not be used in patients with moderate or severe hepatic impairment.The concomitant use of Rasagil and fluoxetine or fluvoxamine should be avoided. At least five weeks shouldelapse between discontinuation of fluoxetine and initiation of treatment with Rasagil. At least 14 days should elapse between discontinuation of Rasagil and initiation of treatment with fluoxetine or fluvoxamine.The concomitant use of Rasagil and dextromethorphan or sympathomimetics such as, those present in nasal and oral decongestants or cold medicinal product containing ephedrine or pseudoephedrine is not recommended.During the clinical development program the occurrence of cases of melanoma prompted the consideration of a possible association with Rasagil. The data collected suggests that Parkinson's disease and not any medicinal products in particular, is associated with a higher risk of skin cancer (not exclusively melanoma). Any suspicious skin lesion should be evaluated by a specialist.
Contraindications
Rasagiline is contraindicated for use with meperidine, tramadol, methadone, propoxyphene and MAO inhibitors (MAOIs), including other selective MAO-B inhibitors, because of risk of serotonin syndrome.